A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
NCT00960661 on ClinicalTrials.gov · last registry update 2015-04-07
An unusually large phase 3: 1,036 participants, more than double the 424 typical for the stage. The sponsor logged completion for August 2012. Primary outcome, as filed: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Enrollment
- 1,036
- Started
- 2009-09
- Primary completion
- 2012-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.